Repurposing of FDA drugs with known efficacy and safety that have inhibitory effects on calpain/Cdk5 signalling pathway could be more appropriate in the management of PD as adjuvant therapeutic remedies. This evidence concerns the gene CDK5 and Parkinson disease.